Biogen faces key test with Ph3 data on oral MS drug

Can Biogen Idec ($BIIB) keep the hits coming? The biotech giant's stock has been at the top of the charts among its peers over the past year, helped considerably by its experimental multiple sclerosis  drug BG-12's performance in late-stage development. With new Phase III data on the potential blockbuster expected within weeks, analysts told Reuters about some of the key factors that could play a...